

Clone (SEQ ID NO)	...P35-L19... linker sequence (nucleotide)	...P35-L19... linker sequence (aminoacid)	Production yields
AKKAS (18/9)	AATGCTTCCGGAGGGGAGCTAAAGGTGGCGGTGGCAAGCAGAGGGGAGGTGAGGTGCAG	NAS GGGAKGGGKAGGGG EVQ	4.6 mg/L
AP7 (19/15)	AATGCTTCCGACACAGCACCAGCACCAGCACAGCACACAGCACCAGAGGTGCAG	NAS APAPAPAPAPAP EVQ	4.7 mg/L
DDS (20/10)	AATGCTTCCGGAGGTGGGGGTGATGGTGGGGGAGGTGACGGCGGAGGTGGTCTGAGGTGCAG	NAS GGGGDGGGGGGGGG EVQ	5.0 mg/L
AP6 (21/14)	AATGCTTCCGACACAGCACCAGCACCAGCACAGCACACAGCACCAGAGGTGCAG	NAS APAPAPAPAPAP EVQ	3.5 mg/L
(G4S)₃ (22/11)	AATGCTTCCGGTGGAGGCGGGTCAGCGGAGGGGGTTCGGCGGTGGCGGATCGAGGTGCAG	NAS GGGGSGGGSGGGG EVQ	3.5 mg/L
SES (23/12)	AATGCTTCCGGTGGGGGTGGGTCCGGAGCGGAGGGCGAAGCGGAGGTGGTCCGAGGTGCAG	NAS GGGGSGGGGEGGGG EVQ	4.4 mg/L
Alpha3 (24/13)	AATGCTTCCGAGAAAGCAGCAGCAAAAGAGAGCAGCAGCAAAAGAGCAGCAAAAGCAAGGTGCAG	NAS AEAATAKEAAKEAAKA EVQ	4.5 mg/L
SAD (25/4)	AATGCTTCCGGTCTGCAGACGGCGGATCATCAGCTGGGGGAAGTACGCAGAGAGGTGCAG	NAS GSADGGSSAGSSDAG EVQ	9.0 mg/L

Fig. 1A




Fig. 1B





Fig. 2




Fig. 3




Fig. 3 ctd'




Fig. 4




Fig. 4 ctd'




Fig. 5




Fig. 5 ctd'




Fig. 5 ctd'




Fig. 6




Fig. 6 ctd'




Fig. 6 ctd'

[prior art for illustrative purposes]




Fig. 7

[prior art for illustrative purposes]







Fig. 8

A**B****Fig. 9**

C



D




Fig. 9 ctd'





Fig. 10

24 Hours tumor targeting with «Old» variant



24 Hours tumor targeting with «SAD» variant




Fig.11